CANF
Price
$1.84
Change
-$0.04 (-2.12%)
Updated
Oct 22, 04:31 PM (EDT)
Capitalization
4.05M
Intraday BUY SELL Signals
NCEL
Price
$2.56
Change
-$0.27 (-9.54%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
16.35M
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs NCEL

CANF vs NCEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CANF vs. NCEL commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and NCEL is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CANF with price predictions
Oct 21, 2026

CANF's Indicator enters downward trend

The Aroon Indicator for CANF entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 328 similar instances where the Aroon Indicator formed such a pattern. In 284 of the 328 cases the stock moved lower. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANF as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, 35 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 69 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for CANF just turned positive on October 19, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.

Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 154 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.834) is normal, around the industry mean (2.988). P/E Ratio (-0.407) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NCEL with price predictions
Oct 21, 2026

NCEL's RSI Indicator recovers from oversold territory

The RSI Indicator for NCEL moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 33 of the 37 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where NCEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +11.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCEL advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

NCEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NCEL as a result. In 84 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for NCEL turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 35 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for NCEL entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. NCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.707) is normal, around the industry mean (2.988). P/E Ratio (5.054) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CANF: Fundamental Ratings
CANF
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CANFNCEL
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
78%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CANF: $1.89 vs. NCEL: $2.83)
Brand notoriety: CANF and NCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 2% vs. NCEL: 205%
Market capitalization -- CANF: $4.05M vs. NCEL: $16.35M
CANF [@Biotechnology] is valued at $4.05M. NCEL’s [@Biotechnology] market capitalization is $16.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green while NCEL’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • NCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, CANF is a better buy in the long-term than NCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 5 TA indicator(s) are bullish while NCEL’s TA Score has 4 bullish TA indicator(s).

  • CANF’s TA Score: 5 bullish, 3 bearish.
  • NCEL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CANF is a better buy in the short-term than NCEL.

Price Growth

CANF (@Biotechnology) experienced а -2.09% price change this week, while NCEL (@Biotechnology) price change was +8.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.

Industries' Descriptions

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CANF
Daily Signal:
Gain/Loss:
NCEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.02%
GNPX - CANF
93%
Closely correlated
-3.76%
ICU - CANF
91%
Closely correlated
+3.93%
MLEC - CANF
89%
Closely correlated
+3.75%
LONA - CANF
78%
Closely correlated
+7.59%
LNAI - CANF
72%
Closely correlated
+0.58%
More

NCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCEL has been loosely correlated with APVO. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NCEL jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCEL
1D Price
Change %
NCEL100%
+8.43%
APVO - NCEL
63%
Loosely correlated
-0.93%
CANF - NCEL
62%
Loosely correlated
-0.02%
MLEC - NCEL
58%
Loosely correlated
+3.75%
IRON - NCEL
54%
Loosely correlated
-4.38%
CABA - NCEL
47%
Loosely correlated
-4.35%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDSB1.240.28
+29.10%
PDS Biotechnology Corp
BMNR23.961.14
+5.00%
BitMine Immersion Technologies Inc.
FIVN35.290.98
+2.86%
Five9
ADXN3.03-0.02
-0.66%
Addex Therapeutics Ltd
NPB15.13-0.65
-4.12%
Northpointe Bancshares Inc